Alcon Inc. logo

Alcon Inc. (ALC)

Market Open
15 Jun, 18:34
NYSE NYSE
$
66. 17
-0.68
-1.0142%
$
32.58B Market Cap
- P/E Ratio
1.22% Div Yield
1.12M Volume
- Eps
$ 66.85
Previous Close
Add Transaction
Day Range
66.1 68.02
Year Range
61.84 92.55
Want to track ALC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.

Zacks | 1 year ago
Alcon eyes revenue growth in 2025 after in-line results

Alcon eyes revenue growth in 2025 after in-line results

Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.

Reuters | 1 year ago
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings

Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings

Evaluate the expected performance of Alcon (ALC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 1 year ago
Here's Why Alcon (ALC) is a Strong Growth Stock

Here's Why Alcon (ALC) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Needham ups Alcon target, adds to Conviction List

Needham ups Alcon target, adds to Conviction List

Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%)

Thefly | 1 year ago
Reasons to Retain Alcon Stock in Your Portfolio for Now

Reasons to Retain Alcon Stock in Your Portfolio for Now

Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.

Zacks | 1 year ago
Why Alcon (ALC) is a Top Growth Stock for the Long-Term

Why Alcon (ALC) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?

Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Alcon: Q3, Slight Guidance Cut Is Not Something Structural

Alcon: Q3, Slight Guidance Cut Is Not Something Structural

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expected to drive significant growth in the vision segment. Alcon's surgical business, with a strong position in cataract surgery, is projected to grow 7% annually, driven by advanced technology and international expansion.

Seekingalpha | 1 year ago
Alcon (ALC) Q3 2024 Earnings Call Transcript

Alcon (ALC) Q3 2024 Earnings Call Transcript

Alcon Inc. (NYSE:ALC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Dan Cravens - Vice President, Investor Relations Conference Call Participants Graham Doyle - UBS Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co. Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Ryan Zimmerman - BTIG Jeff Johnson - Baird Anthony Petrone - Mizuho Tom Stephan - Stifel Brett Fishbin - Keybanc Capital Markets David Adlington - JP Morgan Giang Nguyen - Citi Issie Kirby - Redburn Atlantic Sajid Aznar - HSBC Falco Freidrichs - Deutsche Bank Operator Greetings and welcome to the Alcon third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.

Zacks | 1 year ago
Loading...
Load More